The incidnce rates of acute kidney injury (AKI) over time have notably increased nowadays, both in patients and community. Taiwan has the highest incidence and prevalence rates of end-stage kidney disease (ESRD) in the world. Hence, chronic kidney disease (CKD) has become a national public health burden. Either dialysis-requiring or non-dialysis-requiring AKI is associated with high mortality, and even minimal elevation of serum creatinine as little as 0.3 mg/dl or mild proteinuria has an unfavorable impact on the outcomes. In light of this, patients who survive AKI have a greater risk for ESRD and higher long-term mortality rate than patients without AKI. These reports indicate a need to broaden the investigation on adverse events that may be associated with AKI.


The purpose of Consortium for Acute Kidney Injury and Renal Diseases (CAKs) is to share the clinical data and research achievements. The vision of CAKs is to advance Taiwan to be one of the leading countries for the international kidney disease clinical trials and new drug application, which aims to provide the patients with newly available drugs in light of the up-to-date new drug developments. By way of integrating with the database of the clinical data, bio-specimen and bio-markers to share with all members and to initial researches is the goal of CAKs. Through strategies to lower the incidence of AKI and clarify the causal nature of the AKI-CKD relationship, further light will be shed on lowering the CKD burden by nipping it in the bud.

Contact Information


Correspondence to: Prof Kwan-Dun Wu, MD

Room 1419, Clinical ResearchBuilding, Department of Internal Medicine, NationalTaiwanUniversityHospital

7 Chung-Shan South Road, Taipei 100, Taiwan

Telephone: +886-2-23562082, Fax: +886-2-23934176